Home / Intelligence / Blog


The Future of Cell Therapy: What’s Next?

November 03, 2020 Executive Summary Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industriallyTo date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approvalThere have been multiple challenges involved when trying to successfully commercialize the products, but the landscape…

Read Now

CAR Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

September 22, 2020 Executive Summary Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatmentKey barriers for CAR T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) MedicareNew opportunities to overcome these hurdles are being pursued in the form of innovative pricing and…

Read Now

Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World

July 14, 2020 Executive Summary Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptakePayers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritizationPharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely…

Read Now

2019 NRDL: Insights for Future Pricing Negotiations in China

June 2, 2020 Executive Summary China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers…

Read Now